ERBB2 and breast carcinoma: The combination of the AI letrozole and the CDK4/6 inhibitor palbociclib was studied in the phase II PALOMA-1 trial, which enrolled postmenopausal women with advanced ER-positive, HER2-negative breast cancer (Finn et al., 2015).